atovaquone has been researched along with Brain Inflammation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR | 1 |
| Fisher, S; Levy, I; Megged, O; Shalit, I; Stein, J; Yaniv, I | 1 |
| Araujo, FG; Remington, JS; Suzuki, Y | 1 |
| Gourdon, D; Katlama, C; Lapierre, D; Mouthon, B; Rousseau, F | 1 |
| Cadman, J; Torres, G | 1 |
| Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL | 1 |
3 trial(s) available for atovaquone and Brain Inflammation
| Article | Year |
|---|---|
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Encephalitis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Reverse Transcriptase Inhibitors; Ritonavir; Toxoplasmosis, Cerebral; Young Adult | 2016 |
Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiprotozoal Agents; Atovaquone; Clindamycin; Encephalitis; Female; Humans; Male; Naphthoquinones; Pyrimethamine; Recurrence; Risk Factors; Sulfadiazine; Survival Analysis; Time Factors; Toxoplasmosis, Cerebral | 1996 |
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Atovaquone; Drug Therapy, Combination; Encephalitis; Female; Follow-Up Studies; Humans; Male; Naphthoquinones; Pyrimethamine; Sulfadiazine; Time Factors; Toxoplasma; Treatment Outcome | 2002 |
3 other study(ies) available for atovaquone and Brain Inflammation
| Article | Year |
|---|---|
Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation.
Topics: Anti-Infective Agents; Atovaquone; Child; Encephalitis; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Time Factors; Toxoplasmosis, Cerebral; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Brain; Clindamycin; Disease Models, Animal; Drug Therapy, Combination; Encephalitis; Female; Mice; Mice, Inbred CBA; Naphthoquinones; Pyrimethamine; Rifabutin; Sulfadiazine; Toxoplasmosis, Cerebral; Treatment Outcome | 1996 |
Optimizing PCP therapy.
Topics: Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; CD4 Lymphocyte Count; Clinical Trials as Topic; Dapsone; Drug Administration Schedule; Encephalitis; Humans; Naphthoquinones; Pentamidine; Pneumonia, Pneumocystis; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination | 1997 |